| 產(chǎn)品編號 | bsm-34222M |
| 英文名稱 | Mouse Anti-DM1 antibody |
| 中文名稱 | DM1重組鼠單抗 |
| 別 名 | Mertansine; Emtansine; Maytansinoid DM1; Maytansinoid DM 1; 139504-50-0; |
| 產(chǎn)品類型 | 小分子抗體 |
| 抗體來源 | Mouse |
| 克隆類型 | Recombinant |
| 克 隆 號 | 7A3 |
| 交叉反應(yīng) | (predicted: DM1) |
| 產(chǎn)品應(yīng)用 | ELISA=1:5000-20000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | kDa |
| 檢測分子量 | |
| 性 狀 | Liquid |
| 免 疫 原 | DM1 coupled with OVA |
| 亞 型 | IgG1 |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.02% Proclin300. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Mertansine, also called DM1 (and in some of its forms emtansine), is a thiol-containing maytansinoid that for therapeutic purposes is attached to a monoclonal antibody through reaction of the thiol group with a linker structure to create an antibody-drug conjugate (ADC). Mertansine is a tubulin inhibitor, meaning that it inhibits the assembly of microtubules by binding to tubulin (at the rhizoxin binding site). The monoclonal antibody binds specifically to a structure (usually a protein) occurring in a tumour, thus directing mertansine into this tumour. This concept is called targeted therapy. Trastuzumab emtansine also known as ado-trastuzumab emtansine and sold under the trade name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoes receptor-mediated internalization into cells, is catabolized in lysosomes where DM1-containing catabolites are released and subsequently bind tubulin to cause mitotic arrest and cell death. Trastuzumab binding to HER2 prevents homodimerization or heterodimerization (HER2/HER3) of the receptor, ultimately inhibiting the activation of MAPK and PI3K/AKT cellular signalling pathways. Because the monoclonal antibody targets HER2, and HER2 is only over-expressed in cancer cells, the conjugate delivers the cytotoxic agent DM1 specifically to tumor cells.
|
